Powered by the industry’s largest set of digitized protocols and operational data, Braid enables smarter trial design and greater operational efficiency
Advarra, a market leader in regulatory reviews and a trusted provider of clinical research technology, has announced the launch of Braid, a production-ready AI engine designed to transform clinical trial operations. Backed by the industry’s largest and most comprehensive clinical trial operations dataset, Braid delivers actionable insights and automation capabilities that help sponsors, CROs, and research sites design and execute trials more efficiently.
Braid’s competitive advantage lies in its data foundation. Drawing from Advarra’s institutional review board (IRB) records and clinical trial systems, it leverages operational and protocol-related data from more than 30,000 studies conducted by over 3,500 sponsors. This includes metrics such as startup cycle times, enrollment patterns, and study modifications. By curating and integrating this data with standardized ontologies, Braid ensures seamless harmonization with other datasets, enabling advanced analytics and agentic AI capabilities.
“For years, operational data has been buried in static study documents and fragmented eClinical systems, too unstructured to access at scale,” said Laura Russell, SVP, head of data and AI product development at Advarra. “Braid changes that. It unlocks operational data across the entire trial lifecycle, capturing important milestones such as study design modifications as the study progresses, not just at a single point in time. This allows us to learn lessons from past trials and generate intelligence that improves how research is planned, executed, and scaled.”
The AI engine supports the entire trial lifecycle, offering coordinated research capabilities while reducing the workload on study teams, sites, and participants. It enables intelligent agents within Advarra products and third-party systems to automate workflows, streamline operations, and enhance decision-making. Over time, Braid continuously learns, improving operational speed, reducing burdens, and enhancing precision.
Also Read: ARCHIMED Acquires Arkstone to Boost AI Healthcare Tools
“Advarra’s unmatched access to trial operations data and deep domain expertise uniquely position us to tackle the complex challenges of creating structured, context-aware data and operationally useful models models that capture the nuance and precision clinical research demands,” said Gadi Saarony, CEO at Advarra. “While all decisions related to ethical review and participant protection are and will continue to be made by people, not AI, we’re actively exploring how AI can enhance Advarra’s systems and operations, enabling us to better support research stakeholders. This is part of our broader commitment to advancing innovation and efficient, ethical, and compliant research, and why we’re continuing to invest in our AI capabilities and technology leadership team.”
Advarra is already deploying Braid across multiple use cases. The first Braid-powered product will focus on data-driven study design optimization, introducing dynamic protocol engineering to align trial designs with operational realities. This includes identifying overly complex visit schedules, flagging restrictive eligibility criteria that may slow recruitment, and suggesting startup timelines based on historical site performance all aimed at reducing costs, shortening timelines, and easing burdens on sites and patients.
Saarony added, “While we have a bold vision for AI in clinical trials, we’re building at the speed of trust. For decades, Advarra has helped sponsors, CROs, and sites worldwide navigate clinical research with confidence and integrity. And we’re doing the same with AI. We’re committed to developing AI solutions that combine innovation and insights with human-in-the-loop judgment and context, and are guided by ethics, grounded in scientific rigor, and shaped by deep operational expertise.”
